http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#Head
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#assertion
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#provenance
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#pubinfo
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#assertion
http://purl.obolibrary.org/obo/DOID_409
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_409
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00973
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#association
http://www.w3.org/2000/01/rdf-schema#label
"Ezetimibe Tablet is contraindicated in the following conditions: The combination of Ezetimibe Tablets with a statin is contraindicated in patients with active liver disease or unexplained persistent elevations in hepatic transaminase levels. Women who are pregnant or may become pregnant. Because statins decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, Ezetimibe Tablets in combination with a statin may cause fetal harm when administered to pregnant women. Additionally, there is no apparent benefit to therapy during pregnancy, and safety in pregnant women has not been established. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus and the lack of known clinical benefit with continued use during pregnancy. [See Use in Specific Populations ( 8.1 Nursing mothers. Because statins may pass into breast milk, and because statins have the potential to cause serious adverse reactions in nursing infants, women who require Ezetimibe Tablets treatment in combination with a statin should be advised not to nurse their infants [see Use in Specific Populations ( 8.3 Patients with a known hypersensitivity to any component of this product. Hypersensitivity reactions including anaphylaxis, angioedema, rash and urticaria have been reported with Ezetimibe Tablets [see Adverse Reactions ( 6.2 * Statin contraindications apply when Ezetimibe Tablet is used with a statin: Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels ( 4 5.2 Women who are pregnant or may become pregnant ( 4 8.1 Nursing mothers ( 4 8.3 Known hypersensitivity to product components ( 4 6.2"
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#association
https://w3id.org/biolink/vocab/relation
https://schema.org/MedicalContraindication
https://identifiers.org/drugbank:DB00973
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#provenance
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#pubinfo
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#sig
http://purl.org/nanopub/x/hasSignature
EXmqaUdQyZRGcJGF0oQnB2YCW08ZljzJuMC9toTdN460BYU9PsStW5yeTUtEnmwImCMOmXi4HnKVKPF8KtbQ4KlDB/jfCBBOSdl2UJj2PEHk2b6HpiJJKygGnp4f/9zDIPn3UyHf9e/BnhamhlCMs+meh80QjupE6WXkc1Yuino=
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM
http://purl.org/dc/terms/created
2021-08-23T12:34:30.728+02:00
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAdPYbqrw78HgJe2wrq065UYQeIIeJT1hSABLC3OT9HMM
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY